$23.96
Viridian Therapeutics is a biotechnology business based in the US. Viridian Therapeutics shares (VRDN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $24.57 – an increase of 2.2% over the previous week. Viridian Therapeutics employs 94 staff and has a trailing 12-month revenue of around $288,000.
What's in this guide?
Our top picks for where to buy Viridian Therapeutics stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Viridian Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – VRDN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Viridian Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Viridian Therapeutics stock price (NASDAQ: VRDN)
Use our graph to track the performance of VRDN stocks over time.Viridian Therapeutics shares at a glance
Latest market close | $24.57 |
---|---|
52-week range | $10.93 - $24.75 |
50-day moving average | $18.79 |
200-day moving average | $16.91 |
Wall St. target price | $39.56 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-4.25 |
Is it a good time to buy Viridian Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Viridian Therapeutics price performance over time
Historical closes compared with the close of $24.98 from 2024-10-18
1 week (2024-10-15) | 3.91% |
---|---|
1 month (2024-09-20) | 12.02% |
3 months (2024-07-22) | 66.76% |
6 months (2024-04-22) | 74.69% |
1 year (2023-10-20) | 115.72% |
---|---|
2 years (2022-10-21) | 24.84% |
3 years (2021-10-22) | 54.39% |
5 years (2019-10-22) | 92.30% |
Viridian Therapeutics financials
Revenue TTM | $288,000 |
---|---|
Gross profit TTM | $-99,122,000 |
Return on assets TTM | -33.45% |
Return on equity TTM | -53.97% |
Profit margin | 0% |
Book value | $5.16 |
Market Capitalization | $1.8 billion |
TTM: trailing 12 months
Viridian Therapeutics share dividends
We're not expecting Viridian Therapeutics to pay a dividend over the next 12 months.
Have Viridian Therapeutics's shares ever split?
Viridian Therapeutics's shares were split on a 1:15 basis on 12 November 2020 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Viridian Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Viridian Therapeutics shares which in turn could have impacted Viridian Therapeutics's share price.
Viridian Therapeutics share price volatility
Over the last 12 months, Viridian Therapeutics's shares have ranged in value from as little as $10.925 up to $24.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viridian Therapeutics's is 1.091. This would suggest that Viridian Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Viridian Therapeutics overview
Viridian Therapeutics, Inc. , a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc.
Frequently asked questions
What percentage of Viridian Therapeutics is owned by insiders or institutions?Currently 0.007% of Viridian Therapeutics shares are held by insiders and 95.143% by institutions. How many people work for Viridian Therapeutics?
Latest data suggests 94 work at Viridian Therapeutics. When does the fiscal year end for Viridian Therapeutics?
Viridian Therapeutics's fiscal year ends in December. Where is Viridian Therapeutics based?
Viridian Therapeutics's address is: 221 Crescent Street, Waltham, MA, United States, 02453 What is Viridian Therapeutics's ISIN number?
Viridian Therapeutics's international securities identification number is: US92790C1045
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question